Opsoclonus-myoclonus Syndrome in a Female Breast Cancer Patient: A Case Report and Literature Review.

IF 1.7 4区医学 Q4 ONCOLOGY

Anticancer research Pub Date : 2025-09-01 DOI:10.21873/anticanres.17761

Calogero Cipolla, Vittorio Gebbia, Vincenzo DI Stefano, Christian Messina, Daniela Sambataro, Filippo Brighina, Chiara Mesi, Martina Greco, Andrea Cortigiani, Maria Rosaria Valerio

{"title":"Opsoclonus-myoclonus Syndrome in a Female Breast Cancer Patient: A Case Report and Literature Review.","authors":"Calogero Cipolla, Vittorio Gebbia, Vincenzo DI Stefano, Christian Messina, Daniela Sambataro, Filippo Brighina, Chiara Mesi, Martina Greco, Andrea Cortigiani, Maria Rosaria Valerio","doi":"10.21873/anticanres.17761","DOIUrl":null,"url":null,"abstract":"Background/aim: Opsoclonus-myoclonus syndrome (OMS) is rarely associated with breast cancer. This paraneoplastic syndrome poses significant diagnostic and therapeutic challenges for physicians.Case report: This article discusses a case of a 58-year-old Caucasian woman with complex neurological symptoms identified as paraneoplastic OMS due to non-metastatic breast carcinoma. This autoimmune disorder is associated with onco-neural autoantibodies, precisely type II anti-Ri nuclear antibody (ANNA-2), which targets the intracellular Ri antigen (Ri-PNS) and cross-reacts with two neuron-specific antigens. A multidisciplinary approach involving neurologists played a crucial role in case management. Left breast biopsy revealed a poorly differentiated ductal infiltrating carcinoma of the left breast, with 95% positive estrogen receptors, 12% positive progesterone receptors, HER-2 1+, FISH not amplified, and Ki67 at 50%. The patient underwent quadrant surgery for breast cancer and received hormonal therapy with anastrozole. To date, the patient is cancer-free; however, OMS persists. Neurological treatment did not yield significant or durable results. In conclusion, the medical literature on OMS in patients with breast cancer is fragmentary.Conclusion: This report illustrates the complexity of managing breast cancer patients with OMS and reinforces the critical need for a multidisciplinary approach.","PeriodicalId":8072,"journal":{"name":"Anticancer research","volume":"45 9","pages":"4037-4045"},"PeriodicalIF":1.7000,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Anticancer research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.21873/anticanres.17761","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background/aim: Opsoclonus-myoclonus syndrome (OMS) is rarely associated with breast cancer. This paraneoplastic syndrome poses significant diagnostic and therapeutic challenges for physicians.

Case report: This article discusses a case of a 58-year-old Caucasian woman with complex neurological symptoms identified as paraneoplastic OMS due to non-metastatic breast carcinoma. This autoimmune disorder is associated with onco-neural autoantibodies, precisely type II anti-Ri nuclear antibody (ANNA-2), which targets the intracellular Ri antigen (Ri-PNS) and cross-reacts with two neuron-specific antigens. A multidisciplinary approach involving neurologists played a crucial role in case management. Left breast biopsy revealed a poorly differentiated ductal infiltrating carcinoma of the left breast, with 95% positive estrogen receptors, 12% positive progesterone receptors, HER-2 1+, FISH not amplified, and Ki67 at 50%. The patient underwent quadrant surgery for breast cancer and received hormonal therapy with anastrozole. To date, the patient is cancer-free; however, OMS persists. Neurological treatment did not yield significant or durable results. In conclusion, the medical literature on OMS in patients with breast cancer is fragmentary.

Conclusion: This report illustrates the complexity of managing breast cancer patients with OMS and reinforces the critical need for a multidisciplinary approach.

查看原文本刊更多论文

女性乳腺癌患者眼阵挛-肌阵挛综合征1例报告及文献复习。

背景/目的：眼阵挛-肌阵挛综合征（OMS）很少与乳腺癌相关。这种副肿瘤综合征对医生的诊断和治疗提出了重大挑战。病例报告：这篇文章讨论了一个58岁的白人妇女复杂的神经系统症状确定为副肿瘤OMS由于非转移性乳腺癌。这种自身免疫性疾病与肿瘤神经自身抗体有关，确切地说，是II型抗Ri核抗体（ANNA-2），其靶向细胞内Ri抗原（Ri- pns）并与两种神经元特异性抗原发生交叉反应。涉及神经学家的多学科方法在病例管理中发挥了至关重要的作用。左乳活检显示左乳低分化导管浸润性癌，雌激素受体95%阳性，孕激素受体12%阳性，HER-2 1+， FISH未扩增，Ki67 50%。该患者因乳腺癌接受了象限手术并接受了阿那曲唑的激素治疗。到目前为止，患者没有癌症；然而，OMS仍然存在。神经治疗没有产生显著或持久的结果。总之，关于乳腺癌患者OMS的医学文献是零碎的。结论：本报告说明了管理乳腺癌OMS患者的复杂性，并强调了对多学科方法的迫切需要。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Anticancer research 医学-肿瘤学

CiteScore

3.70

自引率

10.00%

发文量

566

审稿时长

2 months

期刊介绍： ANTICANCER RESEARCH is an independent international peer-reviewed journal devoted to the rapid publication of high quality original articles and reviews on all aspects of experimental and clinical oncology. Prompt evaluation of all submitted articles in confidence and rapid publication within 1-2 months of acceptance are guaranteed. ANTICANCER RESEARCH was established in 1981 and is published monthly (bimonthly until the end of 2008). Each annual volume contains twelve issues and index. Each issue may be divided into three parts (A: Reviews, B: Experimental studies, and C: Clinical and Epidemiological studies). Special issues, presenting the proceedings of meetings or groups of papers on topics of significant progress, will also be included in each volume. There is no limitation to the number of pages per issue.